EUVIMEDEUVIMED entdecken
Crossref

Bezafibrate mitigates oxidized‐low density lipoprotein (ox‐LDL)‐induced the attachment of monocytes to endothelial cells: An implication in atherosclerosis

Huijun Huang, Yan Shen iD

Fundamental & Clinical Pharmacology · 2024

DOI: 10.1111/fcp.13025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Huijun Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Eighth People's Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Lipoproteins, LDL, Bezafibrate, Monocytes, Atherosclerosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oxidized forms of low‐density lipoproteins (ox‐LDL)‐associated endothelial dysfunction and subsequent monocyte adhesion play an important role in the development of atherosclerosis (AS). Bezafibrate (BEZ) is a peroxisome proliferator‐activated receptor (pan‐PPAR) agonist licensed as a hypolipidemic drug. However, the effects of BEZ on endothelial dysfunction are less reported.

Objectives

In this study, we aim to investigate the protective effects of BEZ on ox‐LDL‐challenged vascular endothelial cells to evaluate its potential value in treating AS.

Methods

Human aortic endothelial cells (HAECs) and THP‐1 cells were used to establish an In Vitro AS model. Cell Counting Kit‐8 (CCK‐8) assay, Real‐time PCR, Western blot analysis, and Enzyme‐linked immunosorbent assay (ELISA) were used to test the data.

Results

As expected, treatment with BEZ suppressed the expression of vascular endothelial growth factor A (VEGF‐A), tissue factor (TF), Interleukin 12 (IL‐12), tumor necrosis factor (TNF‐α), and monocyte chemoattractant protein‐1 (MCP‐1). BEZ was also found to inhibit ox‐LDL‐induced expression of the endothelial adhesion molecules vascular cellular adhesion molecule‐1 (VCAM‐1) and intercellular adhesion molecule‐1 (ICAM‐1) in HAECs. Correspondingly, BEZ prevented attachment of THP‐1 monocytes to ox‐LDL‐incubated HAECs. Mechanically, BEZ was found to prevent NF‐κB activation by reducing the levels of nuclear NF‐κB p65 and inhibiting luciferase activity of NF‐κB.

Conclusion

Our study revealed the pharmacological function of BEZ in protecting endothelial dysfunction against ox‐LDL, which may provide valuable insight for the clinical application of BEZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoproteins, LDLBezafibrateMonocytesAtherosclerosisEndothelial CellsCell AdhesionHumansHypolipidemic AgentsTHP-1 CellsNF-kappa BCells, Cultured

Stichwörter der Autor:innen

BezafibrateNF‐κBatherosclerosisendothelial dysfunctionox‐LDL

Substanzen

Lipoproteins, LDLBezafibrateoxidized low density lipoproteinHypolipidemic AgentsNF-kappa B

Autor:innen und Institutionen

  • Department of Cardiology, Shanghai Eighth People's Hospital, Shanghai, China.

ORCID-Profile: Yan Shen

Zitieren

APA

Huang, H., & Shen, Y. (2024). Bezafibrate mitigates oxidized‐low density lipoprotein (ox‐LDL)‐induced the attachment of monocytes to endothelial cells: An implication in atherosclerosis. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13025

Vancouver

Huang H, Shen Y. Bezafibrate mitigates oxidized‐low density lipoprotein (ox‐LDL)‐induced the attachment of monocytes to endothelial cells: An implication in atherosclerosis. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.13025

BibTeX
@article{Huang2024,
  author = {Huang, Huijun and Shen, Yan},
  title = {Bezafibrate mitigates oxidized‐low density lipoprotein (ox‐LDL)‐induced the attachment of monocytes to endothelial cells: An implication in atherosclerosis},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/fcp.13025}
}
Kostenlos starten →